Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Despite This Hiccup, Our "Liquid Biopsy" Plays Have Plenty of Room to Run


After doubling in price in just three months, shares of TrovaGene Inc. (Nasdaq: TROV) - the San Diego-based "liquid-biopsy" play we first recommended back on March 11 - have sold off sharply in the past week.

That's not a surprise.

In our initial report, we classified TrovaGene as an ultra-high-risk stock, said to expect a volatile run, and recommended investors be willing to hold the shares for at least two years to ride out the big swings that almost always accompany a high-risk/high-return-potential stock like this one.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK